Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen delivers strong results and advances its strategic ambitions

Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.